PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 5, 2021Clinical Infectious Diseases

Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

View Full Paper
Ask AI
Bookmark
Share

Population

146 nasopharyngeal/oropharyngeal swabs of COVID-19 cases

Key result

Sequencing of 146 COVID-19 swabs in India revealed that 15 (10.3%) contained a combination of L452R and E484Q mutations in the spike protein receptor-binding domain.

Authors

PYPragya D. YadavGSGajanan SapkalPAPriya Abraham

Discussion

Loading...

Member takes

Overview

Detection of L452R+E484Q in Indian isolates warrants vigilance; leaves open effects on transmissibility or immune evasion.

Structured PICO

P
Population
146 nasopharyngeal/oropharyngeal swabs from COVID-19 cases in India sequenced for SARS-CoV-2 variants.
E
Exposure
Sequencing and neutralization with sera of BBV152 vaccinees
O
Outcome
Presence of L452R and E484Q mutations and immunological characteristics

The B.1.617.1 variant with combined L452R and E484Q mutations was identified in COVID-19 cases in India, raising concerns about potential impacts on vaccine efficacy.

Limitations

  • The combined effect of these mutations is still unknown.

Cite This Study

Yadav et al. (2021) conducted a letter in COVID-19 (n=146). SARS-CoV-2 variant sequencing was evaluated on Presence of combined L452R and E484Q mutations. Sequencing of 146 COVID-19 swabs in India revealed that 15 (10.3%) contained a combination of L452R and E484Q mutations in the spike protein receptor-binding domain.

synapsesocial.com/papers/6a9fa4383b6a4b1faeec6cdchttps://doi.org/10.1093/cid/ciab411
View Full Paper
Ask AI
Bookmark
Share